Nordic Society of Gynaecological Oncology - Clinical Trials Unit
21
2
4
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
14.3%
3 terminated/withdrawn out of 21 trials
81.3%
-5.3% vs industry average
33%
7 trials in Phase 3/4
0%
0 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Role: collaborator
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
Role: lead
Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer
Role: lead
Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer
Role: lead
Trial in Patients With Relapsed Ovarian Cancer
Role: lead
Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer
Role: lead
A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Role: collaborator
Palliation in Gynae-oncology: Patients Expectations and Assessment of Care (PEACE)
Role: lead
APX005M in Patients With Recurrent Ovarian Cancer
Role: lead
Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer
Role: lead
Platine, Avastin and OLAparib in 1st Line
Role: collaborator
Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer
Role: collaborator
Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
Role: lead
Rucaparib Maintenance Therapy in Advanced Cervical Cancer
Role: lead
Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
Role: collaborator
Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane
Role: lead
Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer
Role: collaborator
A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer
Role: lead
Exemestane in Advanced and Recurrent Endometrial Carcinoma
Role: lead
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer
Role: lead